PDF) One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P®/Humate P® treatment in von Willebrand disease patients
CSL Behring Events – EEU 2021
Haemate P Fl 1000 Iu (2400 Iu Vwf) | Apotheek Maes
Clinical use of Haemate® P in inherited von Willebrand's disease: a cohort study on 100 Italian patients | Haematologica
HAEMATE P 2400 UI/1000 UI 1 VIAL POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSION + 1 AMPOLLA DISOLVENTE - Farmacéuticos
EU SUMMARY OF PRODUCT CHARACTERISTICS – EU-SPC (EDS/EU/ENGLISH) HAEMATE® P 250/500/1000
Clinical use of Haemate® P in inherited von Willebrand's disease: a cohort study on 100 Italian patients | Haematologica
Haemate P 1000 IU FVIII:C/2400 IU VWF:Rco | eTabletka
Haemate® P/Humate‐P® for the treatment of von Willebrand disease: considerations for use and clinical experience - AUERSWALD - 2008 - Haemophilia - Wiley Online Library
Dosing | HUMATE-P
Haemate P – BPI
Built on data
Haemate P 1000 I.e. Plv.u.lm zur, zum H.e.Inj.-/Inf.-Lsg. 1 stk
Fachinformation Haemate® P - CSL Behring Österreich
Haemate® P
HAEMATE P 1000 IU (1) MSDS Download
Haemate P CSL Behring
Haemate P CSL Behring
המופיליה - פקטור וון וילבראנד HAEMATE-P Hemophilia - HAEMATE-P Von Willebrand Factor (VWF)
Human plasma-derived von Willebrand factor (HP-VWF/FVIII) | HUMATE-P
SWICA - HAEMATE P Trockensub 1000 IE c Solv + Set
